This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodenburg, J. Articles by Tsimikas, S. Search for Related Content PubMed PubMed Citation Articles by Rodenburg, J. Articles by Tsimikas, S.

Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected Siblings

Effect of Pravastatin

Jessica Rodenburg, MD^_*, Maud N. Vissers, PhD^_*, Albert Wiegman, MD, PhD, Elizabeth R. Miller, BS, Paul M. Ridker, PhD, MD, FACC, Joseph L. Witztum, MD, John J.P. Kastelein, PhD, MD^_* and Sotirios Tsimikas, MD, FACC^,_*

^_* Vascular Medicine
Paediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Department of Medicine, University of California, San Diego, California
Center for Cardiovascular Disease Prevention and Department of Medicine, Harvard Medical School, Boston, Massachusetts

View larger version (10K): [in a new window]   Figure 1 Relationship between oxidized phospholipid (OxPL)/apoprotein B-100 (apoB) and lipoprotein (a) [Lp(a)] in the entire cohort of children with familial hypercholesterolemia at baseline (top) and after two years of pravastatin therapy (bottom). RLU = relative light units.

View larger version (22K): [in a new window]   Figure 2 Mean percent change (with 95% confidence intervals [CIs]) in OxLDL markers from baseline to two years in the placebo and pravastatin groups. Abbreviations as in Table 1.